Sterile Egg Market Report 2026

The sterile egg market size has grown strongly in recent years. It will grow from $1.59 billion in 2025 to $1.72 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to expansion of embryonated egg-based vaccine production, growth of pharmaceutical research activities, increasing laboratory safety requirements, establishment of controlled poultry facilities, rising demand from diagnostic applications.

The sterile egg market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growing investments in vaccine development, rising focus on pandemic preparedness, expansion of biologics manufacturing capacity, increasing regulatory emphasis on sterile inputs, advancements in controlled biological production systems. Major trends in the forecast period include increasing demand for pathogen-free biological inputs, expansion of egg-based vaccine manufacturing, growing use in biopharmaceutical research, enhanced focus on biosecurity and traceability, rising adoption of controlled breeding systems.

The rising food safety concerns are expected to drive the growth of the sterile egg market in the coming years. Food safety concerns refer to potential risks from food contamination, adulteration, or poor hygiene that can pose health hazards to consumers. These concerns are increasing due to the growing use of chemical additives and pesticides in food production, which raises the risk of harmful residues entering the food chain and impacting consumer health. Sterile eggs help address these concerns by eliminating harmful bacteria such as Salmonella through sterilization, providing safer egg-based ingredients for food products and reducing the risk of foodborne illnesses. For example, in October 2024, according to the World Health Organization (WHO), a Switzerland-based UN agency coordinating international public health responses, an estimated 600 million people, nearly one in ten globally, fall ill each year from contaminated food, resulting in approximately 420,000 deaths annually. Therefore, the growing food safety concerns are contributing to the expansion of the sterile egg market.

Key companies operating in the sterile egg market are focusing on innovations such as specific pathogen free (SPF) poultry bio-manufacturing units to enhance disease-free egg production, ensure food safety, and meet the rising demand from pharmaceutical and high-quality food sectors. An SPF poultry bio-manufacturing unit is a facility that produces eggs and poultry free from specific pathogens, ensuring high biosecurity and quality for pharmaceutical and food applications. For instance, in November 2024, Medion AG, a Germany-based consumer electronics company, established Indonesia’s first SPF egg production facility to supply high-quality, disease-free eggs for food and pharmaceutical use. The facility supports national health and biosecurity, reduces import dependency, ensures consistent vaccine inputs, and drives scientific innovation for both animal and human health sectors.

In January 2025, Ba Huân Corporation, a Vietnam-based food company, partnered with Sanovo Technology Group to advance automated egg processing and improve production efficiency. This partnership aims to deliver high-quality, food-safe liquid egg products that meet diverse customer needs while enhancing operational efficiency, food safety, and overall production excellence, positioning Ba Huân as a leader in Vietnam’s egg processing industry. Sanovo Technology Group is a Denmark-based company specializing in egg handling and processing technology.

Major companies operating in the sterile egg market are AVS Bio, Thai SPF Co Ltd, Ovagen Group Limited, SPF Podmoklovo, Immunetic Lifesciences Pvt. Ltd., Valo BioMedia, Nomura Jimusho, Inc., Avian Vaccine Services LLC, Cocalico Biologicals, PSL, SPAFAS, Ovofarm, Charles River AVS Bio, Ovogenics, Charles River Laboratories International, Inc., VALO BioMedia GmbH, JD‑SPF Biotech Co., Ltd., Indovax, Globoaves / GloboBiotech, Beijing Boehringer Ingelheim Vital Biotechnology Co., Ltd, Venky’s (India) Ltd SPF Division, Hy‑Line International, Lohmann Tierzucht GmbH.

North America was the largest region in the sterile egg market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile egg market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sterile egg market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The sterile egg market consists of sales of sterile embryonated eggs, sterile liquid egg products, and pathogen-free eggs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.